What is aTyr Pharma?
aTyr Pharma is dedicated to the discovery and development of groundbreaking medicines by exploring the extracellular functionality and signaling pathways of tRNA synthetases. The company has established a robust global intellectual property portfolio targeting a pipeline of protein compositions derived from 20 tRNA synthetase genes and their associated extracellular targets. Its primary clinical-stage candidate, efzofitimod, is designed to modulate the neuropilin-2 receptor, aiming to downregulate immune engagement in inflammatory lung diseases. This focus positions aTyr Pharma at the forefront of biotherapeutic innovation, addressing unmet needs in complex inflammatory conditions.
How much funding has aTyr Pharma raised?
aTyr Pharma has raised a total of $340.3M across 9 funding rounds:
Series B
$10.5M
Series C
$23M
Debt
$10M
Series D
$49M
Series E
$76M
Stock Offering
$86M
Debt
$20M
Share Placement
$45.8M
Share Placement
$20M
Series B (2007): $10.5M with participation from Alta Partners, Imagene, Cardinal Partners, and Polaris Partners
Series C (2010): $23M led by Alta Partners, Domain Associates, Cardinal Partners, and Polaris Ventures
Debt (2013): $10M supported by Silicon Valley Bank
Series D (2013): $49M featuring Alta Partners, Domain Associates, Cardinal Partners, and Polaris Partners
Series E (2015): $76M backed by T. Rowe Price Associates, Domain Associates, Cardinal Partners, EcoR1 Capital, Polaris Partners, Sphera Global Healthcare, Deerfield, Rock Springs Capital Management, Federated Investors, Alta Partners, and Sofinnova Ventures
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Debt (2016): $20M led by Silicon Valley Bank and Solar Capital
Share Placement (2017): $45.8M supported by Viking Global Investors, Redmile Group, and EcoR1 Capital
Share Placement (2020): $20M featuring Aspire Capital Fund
Key Investors in aTyr Pharma
Alta Partners
Alta Partners is a venture capital firm with a specialization in healthcare and life sciences, committed to backing innovative companies that enhance patient outcomes.
Domain Associates
Domain Associates is an investment advisory firm with a long-standing focus on biotech investments, having supported numerous biopharmaceutical companies through venture funding.
Cardinal Partners
Cardinal Partners is a leading venture capital partnership exclusively focused on healthcare investing, with a particular emphasis on early-stage financing rounds.
What's next for aTyr Pharma?
With a substantial funding history, aTyr Pharma is poised for continued advancement in its clinical development programs. The recent strategic investment signals strong investor confidence in the company's scientific approach and therapeutic potential. Future endeavors will likely concentrate on progressing efzofitimod through clinical trials and expanding its pipeline, leveraging this capital to navigate the complexities of drug development and regulatory approval. The company's trajectory suggests a focus on scaling operations and potentially exploring new therapeutic applications for its unique platform.
See full aTyr Pharma company page
